Veracyte to Release First Quarter 2025 Financial Results on May 7, 2025
Veracyte (VCYT) has scheduled the release of its first quarter 2025 financial results after market close on Wednesday, May 7, 2025. The cancer diagnostics company will follow the release with a conference call and webcast at 4:30 p.m. Eastern Time, where management will discuss the financial performance and provide a business update.
Investors and interested parties can access the live webcast through the company's website, with a replay being made available afterward at the investor relations section.
Veracyte (VCYT) ha programmato la pubblicazione dei suoi risultati finanziari del primo trimestre 2025 dopo la chiusura del mercato di mercoledì 7 maggio 2025. L'azienda specializzata in diagnostica oncologica terrà una conference call e una webcast alle 16:30 ora della costa orientale, durante le quali la direzione discuterà delle performance finanziarie e fornirà un aggiornamento sulle attività aziendali.
Investitori e interessati potranno seguire la diretta streaming attraverso il sito web dell'azienda, con la possibilità di rivedere la registrazione successivamente nella sezione relazioni con gli investitori.
Veracyte (VCYT) ha programado la publicación de sus resultados financieros del primer trimestre de 2025 después del cierre del mercado el miércoles 7 de mayo de 2025. La compañía especializada en diagnóstico oncológico realizará una llamada conferencia y una transmisión en vivo a las 4:30 p.m. hora del Este, donde la dirección analizará el desempeño financiero y ofrecerá una actualización del negocio.
Inversionistas e interesados podrán acceder a la transmisión en vivo a través del sitio web de la empresa, y posteriormente estará disponible la repetición en la sección de relaciones con inversionistas.
Veracyte (VCYT)는 2025년 5월 7일 수요일 장 마감 후 2025년 1분기 재무 실적 발표를 예정하고 있습니다. 암 진단 전문 회사인 Veracyte는 동부 표준시 기준 오후 4시 30분에 컨퍼런스 콜과 웹캐스트를 진행하며, 경영진이 재무 성과를 논의하고 사업 현황을 업데이트할 예정입니다.
투자자 및 관심 있는 분들은 회사 웹사이트를 통해 생중계에 접속할 수 있으며, 이후 투자자 관계 섹션에서 다시보기를 이용할 수 있습니다.
Veracyte (VCYT) a programmé la publication de ses résultats financiers du premier trimestre 2025 après la clôture des marchés, le mercredi 7 mai 2025. La société spécialisée dans le diagnostic du cancer tiendra une conférence téléphonique et une webdiffusion à 16h30, heure de l'Est, au cours desquelles la direction présentera les performances financières et fera un point sur l'activité.
Les investisseurs et les parties intéressées pourront accéder à la diffusion en direct via le site internet de l'entreprise, avec une rediffusion disponible par la suite dans la section relations investisseurs.
Veracyte (VCYT) hat die Veröffentlichung seiner Finanzergebnisse für das erste Quartal 2025 für Mittwoch, den 7. Mai 2025, nach Börsenschluss geplant. Das Unternehmen für Krebsdiagnostik wird im Anschluss eine Telefonkonferenz und einen Webcast um 16:30 Uhr Eastern Time abhalten, bei denen das Management die finanzielle Entwicklung erläutern und ein Unternehmensupdate geben wird.
Investoren und Interessierte können den Live-Webcast über die Website des Unternehmens verfolgen; eine Aufzeichnung wird anschließend im Bereich Investor Relations verfügbar sein.
- None.
- None.
The conference call will be webcast live from the company’s website and will be available via the following link: https://edge.media-server.com/mmc/p/5r4msrbq. A webcast replay will be available following the conclusion of the live broadcast and will be accessible on the company’s website at https://investor.veracyte.com/events-presentations.
The conference call dial-ins can be accessed by registering via this link.
About Veracyte
Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our Veracyte Diagnostics Platform delivers high-performing cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and a powerful evidence-generation engine, which ultimately drives durable reimbursement and guideline inclusion for our tests, along with new insights to support continued innovation and pipeline development. For more information, please visit www.veracyte.com or follow us on LinkedIn or X (Twitter).
View source version on businesswire.com: https://www.businesswire.com/news/home/20250416807036/en/
Investors
Shayla Gorman
investors@veracyte.com
(619) 393-1545
Media
Tracy Morris
media@veracyte.com
(650) 380-4413
Source: Veracyte, Inc.
FAQ
When will Veracyte (VCYT) report Q1 2025 earnings?
How can investors access Veracyte's Q1 2025 earnings call?
What time is Veracyte's Q1 2025 earnings call?
Where can I find the replay of Veracyte's Q1 2025 earnings webcast?
